SCHEMBL6983027

SCHEMBL6983027

COc1ccccc1-c1nc(=S)n(Cc2ccccc2)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 19/20 1.00
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6978905 0.86 CXCR2 (0.75) CXCR2
SCHEMBL6978819 0.82 CXCR2 (1.00) CXCR2
SCHEMBL6973157 0.81 CXCR2 (1.00) CXCR2
SCHEMBL6982245 0.80 CXCR2 (0.67) CXCR2
SCHEMBL6968928 0.80 CXCR2 (1.00) CXCR2
SCHEMBL6981527 0.80 CXCR2 (1.00) CXCR2
SCHEMBL6977448 0.79 CXCR2 (0.70) CXCR2
SCHEMBL6976692 0.79 CXCR2 (1.00) CXCR2
SCHEMBL6976397 0.77 CXCR2 (1.00) CXCR2
SCHEMBL6982733 0.76 CXCR2 (0.71) CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1109790-B1 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS ASTRAZENECA AB (SE) 2003-05-14 EP claimed
US-20020086862-A1 Novel compounds ASTRAZENECA AB 2002-07-04 US claimed
EP-1109790-B1 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS ASTRAZENECA AB (SE) 2003-05-14 EP disclosed
US-20020086862-A1 Novel compounds ASTRAZENECA AB 2002-07-04 US disclosed
EP-1109790-A1 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS AstraZeneca AB (SE) 2001-06-27 EP disclosed
WO-2000012489-A1 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS ASTRAZENECA AB (SE) 2000-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086862-A1 Novel compounds ABCG2, CYP3A4, CYP4B1 CXCR2 568/4885MEN1 2755/4885KMT2A 4259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.